164 related articles for article (PubMed ID: 38541221)
1. Disseminated Enterovirus Infection in a Patient Affected by Follicular Lymphoma Treated with Obinutuzumab: A Case Report and a Narrative Review of the Literature.
Lupia T; Corcione S; Staffilano E; Bosio R; Curtoni A; Busca A; De Rosa FG
Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541221
[No Abstract] [Full Text] [Related]
2. Fatal disseminated enterovirus infection in a patient with follicular lymphoma undergoing obinutuzumab maintenance therapy.
Heger JM; Eichenauer DA; Kasper P; Böll B; Shimabukuro-Vornhagen A; Kochanek M
Eur J Haematol; 2019 Sep; 103(3):268-271. PubMed ID: 31211882
[TBL] [Abstract][Full Text] [Related]
3. Disseminated enterovirus infection in a patient treated with obinutuzumab.
McNeil T; Hannah R; Hui CH; Qiao M
J Med Virol; 2022 Feb; 94(2):439-441. PubMed ID: 34590740
[No Abstract] [Full Text] [Related]
4. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
[TBL] [Abstract][Full Text] [Related]
6. Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.
Thielen FW; Büyükkaramikli NC; Riemsma R; Fayter D; Armstrong N; Wei CY; Huertas Carrera V; Misso K; Worthy G; Kleijnen J; Corro Ramos I
Pharmacoeconomics; 2019 Aug; 37(8):975-984. PubMed ID: 30547368
[TBL] [Abstract][Full Text] [Related]
7. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
Marcus R; Davies A; Ando K; Klapper W; Opat S; Owen C; Phillips E; Sangha R; Schlag R; Seymour JF; Townsend W; Trněný M; Wenger M; Fingerle-Rowson G; Rufibach K; Moore T; Herold M; Hiddemann W
N Engl J Med; 2017 Oct; 377(14):1331-1344. PubMed ID: 28976863
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.
Grigg A; Dyer MJ; Díaz MG; Dreyling M; Rule S; Lei G; Knapp A; Wassner-Fritsch E; Marlton P
Haematologica; 2017 Apr; 102(4):765-772. PubMed ID: 28011903
[TBL] [Abstract][Full Text] [Related]
9. Obinutuzumab in follicular lymphoma.
Martinez-Calle N; Figueroa-Mora R; Villar-Fernandez S; Marcos-Jubilar M; Panizo C
Drugs Today (Barc); 2016 Dec; 52(12):643-651. PubMed ID: 28276536
[TBL] [Abstract][Full Text] [Related]
10. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
[TBL] [Abstract][Full Text] [Related]
11. Coxsackievirus A16 encephalitis during obinutuzumab therapy, Belgium, 2013.
Eyckmans T; Wollants E; Janssens A; Schoemans H; Lagrou K; Wauters J; Maertens J
Emerg Infect Dis; 2014 May; 20(5):913-5. PubMed ID: 24751368
[No Abstract] [Full Text] [Related]
12. Early efficacy and safety of obinutuzumab with chemotherapy in previously untreated patients with follicular lymphoma: A real-world retrospective report of the Polish Lymphoma Research Group.
Paszkiewicz-Kozik E; Hus I; Palka M; Dębowska M; Końska A; Kotarska M; Tyczyńska A; Joks M; Twardosz M; Giza A; Wąsik-Szczepanek E; Kalicińska E; Wiśniewska A; Morawska M; Lewicka B; Szymański M; Targoński Ł; Romejko-Jarosińska J; Drozd-Sokołowska J; Subocz E; Swoboda R; Długosz-Danecka M; Lech-Maranda E; Walewski J
Adv Clin Exp Med; 2023 Jan; 32(1):131-136. PubMed ID: 36603138
[TBL] [Abstract][Full Text] [Related]
13. Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab.
Franceschini E; Pellegrino M; Todisco V; Dolci G; Bettelli F; Meschiari M; Bedini A; Fregni-Serpini G; Grottola A; Guaraldi G; Pecorari M; Sarti M; Luppi M; Perno CF; Mussini C
Infection; 2023 Oct; 51(5):1577-1581. PubMed ID: 37076752
[TBL] [Abstract][Full Text] [Related]
14. The societal impact of obinutuzumab in the first-line treatment of patients with follicular lymphoma in Germany.
Hofmann S; Himmler S; Ostwald D; Dünzinger U; Launonen A; Thuresson PO
J Comp Eff Res; 2020 Oct; 9(14):1017-1026. PubMed ID: 33016109
[TBL] [Abstract][Full Text] [Related]
15. Disseminated Enteroviral Infection Associated with Obinutuzumab.
Dendle C; Gilbertson M; Korman TM; Golder V; Morand E; Opat S
Emerg Infect Dis; 2015 Sep; 21(9):1661-3. PubMed ID: 26291712
[TBL] [Abstract][Full Text] [Related]
16. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).
Radford J; Davies A; Cartron G; Morschhauser F; Salles G; Marcus R; Wenger M; Lei G; Wassner-Fritsch E; Vitolo U
Blood; 2013 Aug; 122(7):1137-43. PubMed ID: 23843495
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma.
Davies A; Trask P; Demeter J; Florschütz A; Hänel M; Kinoshita T; Pettengell R; Quach H; Robinson S; Sadullah S; Sancho JM; Udvardy M; Witzens-Harig M; Knapp A; Liu W
Ann Hematol; 2020 Dec; 99(12):2837-2846. PubMed ID: 32314038
[TBL] [Abstract][Full Text] [Related]
18. Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma.
Dhillon S
Target Oncol; 2017 Apr; 12(2):255-262. PubMed ID: 28324270
[TBL] [Abstract][Full Text] [Related]
19. Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States.
Guzauskas GF; Masaquel A; Thuresson PO; Dawson K; Veenstra DL
Leuk Lymphoma; 2019 Jul; 60(7):1668-1676. PubMed ID: 30632837
[TBL] [Abstract][Full Text] [Related]
20. Prolonged COVID-19 in an Immunocompromised Patient Treated with Obinutuzumab and Bendamustine for Follicular Lymphoma.
Ueda Y; Asakura S; Wada S; Saito T; Yano T
Intern Med; 2022 Aug; 61(16):2523-2526. PubMed ID: 35650124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
